Clofarabine Acts as Radiosensitizer In Vitro and In Vivo by Interfering With DNA Damage Response

International Journal of Radiation Oncology Biology Physics

Volumn 70, Issue 1, 2008, Pages 213-220

  Cariveau, Mickael J ^a   Stackhouse, Murray ^a   Cui, Xiao li ^a   Tiwari, Kamal ^a   Waud, William ^a   Secrist III, John A ^a   Xu, Bo ^a,b  

^a SOUTHERN RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Clofarabine; DNA damage; Nucleoside analogue; Radiosensitizer; Radiotherapy

Indexed keywords

CHEMOTHERAPY; DRUG DELIVERY; RADIOTHERAPY; TUMORS;

DNA DAMAGE RESPONSE; PEDIATRIC LEUKEMIA; PURINE NUCLEOSIDE;

DNA;

CLOFARABINE; FLUOROURACIL; GEMCITABINE; HISTONE H2AX; RADIOSENSITIZING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER MODEL; CANCER RADIOTHERAPY; CLONOGENIC ASSAY; COLONY FORMING UNIT; COLORECTAL CANCER; CONTROLLED STUDY; DNA DAMAGE; DNA STRAND BREAKAGE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIOSENSITIVITY; TUMOR XENOGRAFT;

ADENINE NUCLEOTIDES; ANIMALS; ARABINONUCLEOSIDES; CELL LINE, TUMOR; DNA DAMAGE; DNA REPAIR; DNA, NEOPLASM; HELA CELLS; HISTONES; HUMANS; MALE; MICE; MICE, NUDE; RADIATION DOSAGE; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 37049017587     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.09.012     Document Type: Article

References (34)

1. Boeckman H.J., Trego K.S., and Turchi J.J. Cisplatin sensitizes cancer cells to ionizing radiation via inhibition of nonhomologous end joining. Mol Cancer Res 3 (2005) 277-285
2. McGinn C.J., Shewach D.S., and Lawrence T.S. Radiosensitizing nucleosides. J Natl Cancer Inst 88 (1996) 1193-1203
3. McGinn C.J., and Lawrence T.S. Recent advances in the use of radiosensitizing nucleosides. Semin Radiat Oncol 11 (2001) 270-280
4. Toschi L., Finocchiaro G., Bartolini S., et al. Role of gemcitabine in cancer therapy. Future Oncol 1 (2005) 7-17
5. Khushalani N.I., Leichman C.G., Proulx G., et al. Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: Report of a clinical trial for patients with esophageal cancer. J Clin Oncol 20 (2002) 2844-2850
6. Allen A.M., Zalupski M.M., Robertson J.M., et al. Adjuvant therapy in pancreatic cancer: Phase I trial of radiation dose escalation with concurrent full-dose gemcitabine. Int J Radiat Oncol Biol Phys 59 (2004) 1461-1467
7. Baba H., Suzuki Y., Ema T., et al. [Gemcitabine concurrent with radiation for locally advanced pancreatic cancer]. Gan To Kagaku Ryoho 32 (2005) 1730-1732
8. Bonate P.L., Arthaud L., Cantrell Jr. W.R., et al. Discovery and development of clofarabine: A nucleoside analogue for treating cancer. Nat Rev Drug Discov 5 (2006) 855-863
9. Pui C.H., and Jeha S. Clofarabine. Nat Rev Drug Discov Suppl (2005) S12-S13
10. Sternberg A. Clofarabine. Bioenvision/ILEX. Curr Opin Invest Drugs 4 (2003) 1479-1487
11. Faderl S., Gandhi V., Keating M.J., et al. The role of clofarabine in hematologic and solid malignancies-Development of a next-generation nucleoside analog. Cancer 103 (2005) 1985-1995
12. Pui C.H., and Jeha S. Clofarabine. Nat Rev Drug Discov Suppl. (2005) S12-S13
13. Sutton M.D., and Walker G.C. Managing DNA polymerases: Coordinating DNA replication, DNA repair, and DNA recombination. Proc Natl Acad Sci USA 98 (2001) 8342-8349
14. Lin Z.P., Belcourt M.F., Carbone R., et al. Excess ribonucleotide reductase R2 subunits coordinate the S phase checkpoint to facilitate DNA damage repair and recovery from replication stress. Biochem Pharmacol 73 (2007) 760-772
15. Pauwels B., Korst A.E., Pattyn G.G., et al. Cell cycle effect of gemcitabine and its role in the radiosensitizing mechanism in vitro. Int J Radiat Oncol Biol Phys 57 (2003) 1075-1083
16. Giovannetti E., Mey V., Danesi R., et al. Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines. Clin Cancer Res 10 (2004) 2936-2943
17. Celeste A., Fernandez-Capetillo O., Kruhlak M.J., et al. Histone H2AX phosphorylation is dispensable for the initial recognition of DNA breaks. Nat Cell Biol 5 (2003) 675-679
18. Rogakou E.P., Pilch D.R., Orr A.H., et al. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 273 (1998) 5858-5868
19. Bonate P.L., Arthaud L., Cantrell Jr. W.R., et al. Discovery and development of clofarabine: A nucleoside analogue for treating cancer. Nat Rev Drug Discov 5 (2006) 855-863
20. Gandhi V., Plunkett W., Bonate P.L., et al. Clinical and pharmacokinetic study of clofarabine in chronic lymphocytic leukemia: Strategy for treatment. Clin Cancer Res 12 (2006) 4011-4017
21. Jeha S., Gaynon P.S., Razzouk B.I., et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol 24 (2006) 1917-1923
22. Jeha S., and Kantarjian H. Clofarabine for the treatment of acute lymphoblastic leukemia. Expert Rev Anticancer Ther 7 (2007) 113-118
23. Faderl S., Gandhi V., Keating M.J., et al. The role of clofarabine in hematologic and solid malignancies-Development of a next-generation nucleoside analog. Cancer 103 (2005) 1985-1995
24. Abraham R.T. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev 15 (2001) 2177-2196
25. Shiloh Y. ATM and related protein kinases: Safeguarding genome integrity. Nat Rev Cancer 3 (2003) 155-168
26. Lim D.S., Kim S.T., Xu B., et al. ATM phosphorylates p95/NBS1 in an S-phase checkpoint pathway. Nature 404 (2000) 613-617
27. Kobayashi J., Tauchi H., Sakamoto S., et al. NBS1 localizes to gamma-H2AX foci through interaction with the FHA/BRCT domain. Curr Biol 12 (2002) 1846-1851
28. Kobayashi J. Molecular mechanism of the recruitment of NBS1/hMRE11/hRAD50 complex to DNA double-strand breaks: NBS1 binds to gamma-H2AX through FHA/BRCT domain. J Radiat Res (Tokyo) 45 (2004) 473-478
29. Robinson B.W., Im M.M., Ljungman M., et al. Enhanced radiosensitization with gemcitabine in mismatch repair-deficient HCT116 cells. Cancer Res 63 (2003) 6935-6941
30. Karnitz L.M., Flatten K.S., Wagner J.M., et al. Gemcitabine-induced activation of checkpoint signaling pathways that affect tumor cell survival. Mol Pharmacol 68 (2005) 1636-1644
31. Mason K.A., Milas L., Hunter N.R., et al. Maximizing therapeutic gain with gemcitabine and fractionated radiation. Int J Radiat Oncol Biol Phys 44 (1999) 1125-1135
32. Fields M.T., Eisbruch A., Normolle D., et al. Radiosensitization produced in vivo by once- vs. twice-weekly 2′2′-difluoro-2′-deoxycytidine (gemcitabine). Int J Radiat Oncol Biol Phys 47 (2000) 785-791
33. Yamauchi T., Nowak B.J., Keating M.J., et al. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res 7 (2001) 3580-3589
34. Karp J.E., Ricklis R.M., Balakrishnan K., et al. A phase I clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias. Blood 110 (2007) 1762-1769